11C-methione vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: Preliminary results

In Vivo

Volumn 23, Issue 1, 2009, Pages 105-110

  Ghigi, Giulia ^a   Micera, Renato ^a   Maffione, Anna Margherita ^a   Castellucci, Paolo ^a   Cammelli, Silvia ^a   Ammendolia, Ilario ^a   Nanni, Cristina ^a   Barbieri, Enza ^a   Grassetto, Gaia ^b   Fanti, Stefano ^a   Rubello, Domenico ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

FDG; Huvos classification; Methionine; PET; Soft tissue sarcoma; TRG

Indexed keywords

EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHIONINE C 11; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TUMOR LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; RADIOLOGICAL PARAMETERS; SOFT TISSUE SARCOMA; STANDARDIZED UPTAKE VALUE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; CANCER STAGING; EVALUATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTIVE VALUE; SARCOMA; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63049104030     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Santoro A and Sarcomi I (ed.). Medico-Scientifiche Pavia, 1994.
2. Iagaru A, Quon A, McDougall IR and Gambhir SS: F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med 31: 754-760, 2006.
3. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W and Hoekstra HJ: The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30: 83-101, 2004.
4. Lucas JD, O'Doherty MJ, Wong JC, Bingham JB, McKee PH, Fletcher CD and Smith MA: Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 80: 441-447, 1998.
5. 18FDG uptake in soft tissue masses. Eur J Nucl Med 26: 22-30, 1998.
6. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd and Eary JF: Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103: 339-348, 2005.
7. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T and Herfarth C: Clinical value of (18-F) fluorodeoxyglucose positron emission tomography imaging in ssoft tissue sarcomas. Ann Surg 231: 380-386, 2000.
8. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlelation with grading. J Nucl Med 42: 713-720, 2001.
9. Bredella MA, Caputo GR and Steinbach LS: Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Am J Roentgenol 179: 1145-1150, 2002.
10. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32: 201-208, 2003.
11. Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM and Siegel BA: PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 182: 185-194, 1992.
12. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44: 717-724, 2003.
13. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, Finn RD, Rosenberg SA and Larson SM: Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29: 181-186, 1988.
14. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, Koops HS and Vaalburg W: Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 37: 257-261, 1996.
15. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH and Smith MA: Prospective evaluation of soft tissue masses and sarcomas using flurodeoxyglucose positron emission tomography. Br J Surg 86: 550-556, 1999.
16. Vernon CB, Eary JF, Rubin BP, Conrad EU 3rd, and Schuetze S: FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol 32: 139-142, 2003.
17. Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Korkmaz M, Tansey W, Hicks K and Podoloff DA: Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 37: 1472-1476, 1996.
18. Yanagawa T, Watanabe H, Inoue T, Ahmed AR, Tomiyoshi K, Shinozaki T, Oriuchi N, Endo K and Takagishi K: Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J Comput Assist Tomogr 27: 175-182, 2003.
19. Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, Oriuchi N, Tokunaga M, Aoki J, Endo K and Takagishi K: PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 27: 1509-1517, 2000.
20. 11C]-tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med 40: 381-386, 1999.
21. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A and Groshen S: Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106: 55-67, 1983.
22. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, Dewhirst MW, Prescott DM, Friedman HS, Harrelson JM, Scully SP and Coleman RE: Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37: 1438-1444, 1996.
23. Brisse H, Ollivier L, Edeline V, Pacquement H, Michon J, Glorion C and Neuenschwander S: Imging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 34: 595-605, 2004.
24. Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD and Eary JF: Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 94: 3277-3284, 2002.
25. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J and Eilber FC: Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14: 715-720, 2008.